June 29, 2026 Laplace Announces FDA IDE Approval of TRIUMPH Pivotal Trial of Its Transcatheter Tricu
June 29, 2026 Laplace Announces FDA IDE Approval of TRIUMPH Pivotal Trial of Its Transcatheter Tricu
June 29, 2026 Laplace Announces FDA IDE Approval of TRIUMPH Pivotal Trial of Its Transcatheter Tricu
Laplace Interventional today announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) for TRIUMPH, the company's pivotal trial evaluating its Transcatheter Tricuspid Valve Replacement (TTVR) system.
March 8, 2026 Dr. Brandon Jones on his experience with Laplace TTVR System at CRT 2026
June 29, 2026 Laplace Announces FDA IDE Approval of TRIUMPH Pivotal Trial of Its Transcatheter Tricu
June 29, 2026 Laplace Announces FDA IDE Approval of TRIUMPH Pivotal Trial of Its Transcatheter Tricu
March 8, 2026 Dr. Brandon Jones presents on Laplace EFS Results out to 6 months at CRT 2026
Oct 24, 2025 Laplace Interventional completes Trans-Jugular US EFS and adds Trans-Femoral approach
Oct 24, 2025 Laplace Interventional completes Trans-Jugular US EFS and adds Trans-Femoral approach
Oct 24, 2025 Laplace Interventional completes Trans-Jugular US EFS and adds Trans-Femoral approach
Oct 24, 2025 Laplace Interventional completes Trans-Jugular US EFS and adds Trans-Femoral approach
Oct 24, 2025 Laplace Interventional completes Trans-Jugular US EFS and adds Trans-Femoral approach
Laplace announces two major achievements: successful completion of patient enrollment in its US Early Feasibility Study (EFS) on its Trans-jugular (TJ) system and successful treatment of first two patients with their Trans-femoral (TF) delivery system.
June 26, 2025 Dr. Brandon Jones presents a Laplace TTVR EFS Update at New York Valves
June 26, 2025 Dr. Pradeep Yadav presents a Laplace TTVR Case Review at New York Valves
June 26, 2025 Dr. Pradeep Yadav presents a Laplace TTVR Case Review at New York Valves
Mar 16, 2025 Laplace Interventional: $22M Series C Fundraise
March 9, 2025 Dr. Kashish Goel on his experience with Laplace TTVR System at CRT 2025
June 26, 2025 Dr. Pradeep Yadav presents a Laplace TTVR Case Review at New York Valves
Laplace Interventional Inc. Announces Series C Financing of $22M for its Transcatheter Tricuspid Valve Technology
March 10, 2025 Dr. Kashish Goel presents on Laplace TTVR System at CRT 2025
March 9, 2025 Dr. Kashish Goel on his experience with Laplace TTVR System at CRT 2025
March 9, 2025 Dr. Kashish Goel on his experience with Laplace TTVR System at CRT 2025
March 9, 2025 Dr. Kashish Goel on his experience with Laplace TTVR System at CRT 2025
March 9, 2025 Dr. Kashish Goel on his experience with Laplace TTVR System at CRT 2025
March 9, 2025 Dr. Kashish Goel on his experience with Laplace TTVR System at CRT 2025
November 24, 2024 Dr. Kashish Goel presents on Laplace TTVR System at PCR London Valves
October 28, 2024 Dr. Pradeep Yadav presents on Laplace TTVR System Early Feasibility results at TCT
October 28, 2024 Dr. Pradeep Yadav presents on Laplace TTVR System Early Feasibility results at TCT
October 28, 2024 Dr. Pradeep Yadav presents on Laplace TTVR System Early Feasibility results at TCT
October 28, 2024 Dr. Pradeep Yadav presents on Laplace TTVR System Early Feasibility results at TCT
October 28, 2024 Dr. Pradeep Yadav presents on Laplace TTVR System Early Feasibility results at TCT
June 6, 2024 Dr. Thomas Waggoner presents on Laplace TTVR System FIH results at New York Valves 2024
October 28, 2024 Dr. Pradeep Yadav presents on Laplace TTVR System Early Feasibility results at TCT
June 6, 2024 Dr. Thomas Waggoner presents on Laplace TTVR System FIH results at New York Valves 2024
Feb 26, 2024 Laplace Interventional begins the US EFS of their TTVR system
Feb 26, 2024 Laplace Interventional begins the US EFS of their TTVR system
June 6, 2024 Dr. Thomas Waggoner presents on Laplace TTVR System FIH results at New York Valves 2024
Laplace Interventional Inc. Announces Successful First in Human Procedure in Early Feasibility Study of its Transcatheter Tricuspid Valve Replacement Device.
July 24, 2023 Laplace Interventional: $12.9M Series B Fundraise
Feb 26, 2024 Laplace Interventional begins the US EFS of their TTVR system
July 24, 2023 Laplace Interventional: $12.9M Series B Fundraise
The Series B financing was co-led by ShangBay Capital along with Features Capital in addition to participation from Engage Venture Partners, JWC Ventures and a global strategic investor. Laplace Interventional plans to use the funds raised from this round to pursue their First-in-Human (FIH) and clinical feasibility evaluation of its transcatheter valve system.
Sep 1, 2021: Laplace Interventional: $7.9M Series A Fundraise
Feb 26, 2024 Laplace Interventional begins the US EFS of their TTVR system
July 24, 2023 Laplace Interventional: $12.9M Series B Fundraise
The Series A was led by a major strategic investor along with a significant investment from ShangBay Capital as well as other investors. Laplace Interventional plans to use the funds raised from this round towards achieving its preclinical milestones.